Document:

Exhibit 10.1

SEPARATION
AGREEMENT

AND GENERAL RELEASE

This Separation Agreement
and General Release (the “Agreement”) is made and entered into between Patrick
J. Byrne (hereinafter referred to as “Byrne”) and Agilent Technologies, Inc. (“Agilent”).  The purpose of this Agreement is to document
Byrne’s resignation as Senior Vice President of Agilent and President of the
Electronics Measurement Group, effective March 21, 2007 (as documented in Exhibit A to this Agreement), and Byrne’s termination of
employment from Agilent, effective on or before November 1, 2007, on terms that
are satisfactory both to Agilent and to Byrne. 
Therefore, Agilent and Byrne agree as follows:

1.               In exchange for the
promises set forth in this Agreement, Agilent agrees as follows:

a.               “Interim Period”
— Subject to the provisions of Paragraph 1(b) below, from March 22, 2007
through the close of business on November 1, 2007, Byrne will remain employed
by Agilent but will no longer be actively performing work for Agilent (the “Interim
Period”).  Byrne will continue to receive
his base salary during the Interim Period, which will be at the same rate per
annum as his base salary as of March 22, 2007.  If Byrne’s employment terminates before
November 1, 2007, pursuant to Paragraph 1(b), Byrne will receive his base
salary up to the date his employment terminates.

b.              Termination Date
— Byrne will be designated as a participant in Agilent’s Workforce Management
Program with a termination date of the close of business on November 1,
2007, subject to earlier termination pursuant to the provisions of this
Paragraph.  Byrne’s employment with
Agilent may not extend beyond November 1, 2007.

i)                 No Alternative
Employment During Interim Period — if Byrne does not accept or otherwise
secure alternative employment (including consulting or self employment) during
the Interim Period, Byrne’s termination date will be the close of business on
November 1, 2007 and all other provisions of this Agreement shall be in
full force and effect.

ii)              Alternative
Employment During Interim Period — Byrne’s employment with Agilent will be
terminated should he accept or otherwise secure alternative employment
(including consulting or self employment) during the Interim Period that is not
otherwise approved by Agilent (as described in this Paragraph). Before
accepting or otherwise securing alternative employment, Byrne shall first
notify Agilent’s Chief Executive Officer and Senior Vice President of Human
Resources, in writing, of his intention to do so and shall provide to Agilent
the name of the proposed employer, Byrne’s title and the nature of his
assignment with the proposed employer. 
Within a reasonable period of time after such notification, (but not
longer than 10 business days from the date such notification is received),
Agilent shall provide Byrne with 

 1
 

written
notification of its decision regarding approval or disapproval of Byrne’s
proposed alternative employment.  Agilent
shall not unreasonably withhold consent for Byrne to accept or secure
alternative employment, so long as the proposed alternative employment does not
violate Agilent’s Standards of Business Conduct (including but not limited to
as those Standards apply to employment with an Agilent competitor, supplier,
service provider, customer, and/or reseller). 
If approved in writing by Agilent’s Chief Executive Officer, Byrne’s
employment with Agilent may continue after the acceptance of the proposed
alternative employment.

(1)          Approved Alternative
Employment — if Agilent agrees in writing that Byrne’s proposed alternative
employment during the Interim Period is permissible as not violating Agilent’s
Standards of Business Conduct, Byrne’s employment with Agilent pursuant to this
Agreement shall continue until the close of business on November 1, 2007, and
all other provisions of this Agreement shall remain in full force and effect.

(2)          Disapproved
Alternative Employment — if Agilent informs Byrne that it considers his
proposed alternative employment during the Interim Period to be impermissible
as violating Agilent’s Standards of Business Conduct, Byrne’s employment with
Agilent will terminate immediately on the date he accepts any such alternative
employment, and Byrne will forfeit the following rights: (i) eligibility for
payment of base salary during the remainder of the Interim Period following the
termination date, as detailed in Paragraph 1(a); and (ii) eligibility for Pay
for Results payments for the second half of FY 07, as detailed in Paragraph
1(c).  All other provisions of this
Agreement, including but not limited to Paragraph 1(g) regarding stock options
and Paragraph 1(h) regarding Long Term Performance Program payments, shall
remain in full force and effect if Byrne’s employment terminates before
November 1, 2007 pursuant to this Paragraph.

c.               Pay for Results
— If Byrne remains employed through the last day of the performance period for
the first half of FY 07 (April 30, 2007), he will be eligible to receive Pay
for Results for the first half of FY 07, with a target payment of 80% of Byrne’s
base salary (at the same rate per annum as his base salary as of March 22,
2007) for the first half of FY 07.  If
Byrne remains employed through the last day of the performance period for the
second half of FY 07 (October 31, 2007), he will be eligible to receive Pay for
Results for the second half of FY 07, with a target payment of 80% of Byrne’s
base salary (at the same rate per annum as his base salary as of March 22,
2007) for the second half of FY 07.  Pay
for Results payments are dependent upon the meeting of certain conditions as
set forth in Byrne’s Pay for Results Notification Letter for each respective
fiscal half and applicable plan documents. Payments, if any, made under the Pay
for Results plan will be made within 90 days of the end of the applicable
performance period.

 2
 

d.              Severance Payment
— Within 90 days of the termination of Byrne’s employment, Agilent shall
deliver to Byrne a lump sum payment in the gross amount of Eight Hundred Twenty
Five Thousand Dollars ($825,000.00), inclusive of any payments otherwise
provided for under the Workforce Management Program, less required withholdings
or deductions, representing eighteen months of Byrne’s base salary (at the same
rate per annum as his base salary as of March 22, 2007).

e.               Workforce
Management Program — To designate Byrne as a participant in Agilent’s
Workforce Management Program with a termination date on or before November 1,
2007.  At the time of termination, all
benefits and sums otherwise due will be computed in accordance with Agilent’s
standard procedures and applicable benefit or other plan documents, except as
may otherwise be provided in this Agreement. 
Amounts, if any, determined to be due will be mailed to Byrne’s address
as reflected in Agilent’s records.

f.                 Career
Counseling Payment — Within 90 days of the termination of Byrne’s
employment, Agilent shall provide to Byrne a lump sum payment in the amount of
$25,000, less required deductions, for career counseling.

g.              Stock Options —
Pursuant to the provisions of Agilent’s Workforce Management Program, on Byrne’s
termination date, all unvested stock options will be accelerated and will
become vested.  Byrne will have the
lesser of three months or the expiration date of his options following the date
of termination of his employment to exercise his options.

h.              Long Term
Performance Program — pursuant to the Workforce Management Program
provisions of the Long Term Performance Program (“LTPP”), if Byrne remains
employed at Agilent through the close of business on November 1, 2007, he shall
be entitled to receive LTPP payouts at the full, un-prorated amount, for the
performance periods of FY05-FY07, FY06-FY08, and FY07-FY-09, in accordance with
existing relevant plan documents.  The
target share award (after adjustment for the Verigy dividend) for each of the
above performance periods is as follows, as is the value of the target award
based upon the stock price on the date the target award was established:  (i) for the performance period ending on
October 31, 2007, Byrne was given a target award of 32,029 shares ($750,000);
(ii) for the performance period ending on October 31, 2008, Byrne was given a
target award of 33,079 shares ($1,000,000); and (iii) for the performance
period ending on October 31, 2009, Byrne was given a target award of 33,300 shares
($1,100,000).  If Byrne’s employment with
Agilent terminates before November 1, 2007, pursuant to Paragraph 1(b)(ii)(2),
Byrne’s eligibility to receive LTPP payments will be affected as follows: (i)
for the performance period ending on October 31, 2007, Byrne shall not be
eligible to receive any LTPP payment; (ii) for the performance period ending on
October 31, 2008, Byrne shall be eligible to receive the full, un-prorated LTPP
payment; and (iii) for the performance period ending on October 31, 2009, Byrne
shall be eligible to receive a prorated LTPP payment in accordance with his
termination date and the Workforce Management 

 3
 

Program terms of
the relevant LTPP plan document.  The
payouts, if any, will be based on actual performance measured against the
performance criteria for the relevant performance period.  Awards may range from zero to 200%, and will
be determined by the Compensation Committee following the conclusion of the
relevant three year performance periods. 
The payouts, if any, shall be subject to the terms and conditions set
forth in each of the relevant LTPP plan documents and shall occur at the times
that any awards under the LTPP are paid to other participants in this program
for such performance periods. Unless otherwise deferred under Agilent’s
deferral programs, any shares distributed will be distributed in the calendar
year following the calendar year in which the performance period ends.

i.                  Except as
otherwise stated in this Agreement, Byrne is entitled to exercise employee
benefit conversion privileges upon the same terms and conditions as would be
available to any other voluntarily terminating employee.

j.                  During the
Interim Period, Byrne will continue to be eligible to receive AYCO financial
services or services from any other successor financial service provider that
Agilent offers to its officers through the time that he files his 2007
individual tax return.

k.               During the Interim
Period, Byrne’s medical coverage, Flexible Time Off, deferred compensation,
401(k) plan, Defined Benefit Retirement Plan and Excess Benefit Plan, and
Employee Stock Purchase plan monies, as well as any other benefits not
mentioned above, will be treated in accordance with existing plan documents for
a standard termination.

2.               In exchange
for the promises set forth in this Agreement, Byrne agrees as follows:

a.               Although
Byrne will not be actively performing work for Agilent during the Interim
Period, as an employee of Agilent, Byrne will remain subject to the Standards
of Business Conduct and the Agreement Regarding Confidential Information and
Proprietary Development (“ARCIPD”) signed by Byrne on October 10, 1999 and
attached to this Agreement as Exhibit B. 
During the Interim Period, Byrne will agree to make himself reasonably
available to Agilent upon request to assist in the transition of Byrne’s former
workload to other employees, to answer questions regarding matters assigned to
Byrne before the effective date of his resignation, and to otherwise assist
Agilent in transferring Byrne’s responsibilities to others at Agilent.

b.              To
acknowledge that he is the recipient of confidential and proprietary business
information, and that he will not use or disclose such information except as
may be permitted by Agilent or required by law. 
Byrne acknowledges that the confidentiality obligations of the ARCIPD
survive the termination of his employment. Nothing in this Agreement supersedes
or renders the terms and conditions of the ARCIPD unenforceable or void.  The Agreement will apply 

 4
 

especially
with companies who are competitors of Agilent, including those listed in Exhibit C.

c.               To attend an
Exit Interview on or before November 1, 2007, at which time all appropriate
personnel documents will be executed. 
Byrne further agrees that he will return all company property and
identification on or before May 15, 2007. 
Thereafter, Byrne agrees to do such other acts as may be reasonably
requested by Agilent in order to effectuate the terms of this agreement.

d.              To not make any
public statement or statements to the press concerning Agilent, its business
objectives, its management practices, or other sensitive information without
first receiving Agilent’s written approval. Byrne further agrees not to
disparage Agilent, its officers, directors, employees or agents in any manner likely
to be harmful to them or their business, business reputation or personal
reputation, provided that Byrne may respond accurately and fully to any
question, inquiry or request for information when required by legal process to
do so.

3.               Byrne and Agilent
agree that the Change of Control Severance Agreement between Byrne and Agilent,
dated February 1, 2005, was terminated effective March 22, 2007, and is of no
further force or effect.  All provisions
of this Agreement shall remain in full force and effect should Agilent
experience a Change of Control and Byrne shall remain entitled to all payments
and other benefits as described herein.

4.               In exchange for
Agilent’s doing the acts described in this Agreement, Byrne on behalf of
himself, his heirs, estate, executors, administrators, successors and assigns
does fully release, discharge, and agree to hold harmless Agilent, its
officers, agents, employees, attorneys, employee benefit plans, employee
benefit plan fiduciaries and administrators, consultants, subsidiaries,
affiliated companies, successors and assigns from all actions, causes of
action, claims, judgments, obligations, damages, liabilities, costs, or expense
of whatsoever kind and character which he may have as of the date of execution
of this Agreement, including but not limited
to:

a.               any claims relating
to employment discrimination on account of race, religion, sex, age, national
origin, creed, disability, sexual orientation, or any other basis, whether or
not arising under Title VII of the Civil Rights Act of 1964, the Civil Rights
Act of 1966, the Equal Pay Act of 1963, the Age Discrimination in Employment
Act, California Fair Employment and Housing Act, the Rehabilitation Act of
1973, the Americans With Disabilities Act, any amendments to the foregoing
laws, or any other federal, state, county, municipal, or other law, statute,
regulation or order relating to employment discrimination;

b.              any claims relating
to pay or leave of absence arising under the Fair Labor Standards Act, the
Family Medical Leave Act, any claims relating to Section 806 of the
Sarbanes-Oxley Act of 2002, and any similar laws enacted in California;

 5
 

c.               any claims for
reemployment, salary, wages, bonuses, vacation pay, stock options, acquired
rights, appreciation from stock options, stock appreciation rights, benefits or
other compensation of any kind;

d.              any claims under any
other federal, state or local statutes, ordinances or regulations, including
but not limited to the Employee Retirement Income Security Act of 1974;

e.               any claims relating
to, arising out of, or connected with his employment with Agilent, whether or
not the same be based upon any alleged violation of public policy; compliance
(or lack thereof) with any internal Agilent policy, procedure, practice, or
guideline; or any oral, written, express, and/or implied employment contract or
agreement, or the breach of any term thereof, including but not limited to, any
implied covenant of good faith and fair dealing; or any federal, state, county
or municipal law, statute, regulation, or order whether or not relating to
labor or employment; and

f.                 any claims
relating to, arising out of, or connected with any other matter or event
occurring prior to the execution of this Agreement whether or not brought
before any judicial, administrative, or other tribunal.

g.              Notwithstanding any
provision of this Paragraph, Byrne shall not hereby release any right he may
otherwise have to indemnification by Agilent pursuant to the company’s
certificate of incorporation, by-laws, insurance policies, and applicable law.

5.               Byrne acknowledges
that as of the date of signing this Agreement, he has received all wages and
compensation due to him from Agilent through that time other than those wages
or compensation as described in this Agreement.

6.               In entering into
this Agreement, the parties have intended that this Agreement be a full and
final settlement of all matters, whether or not presently disputed, that could
have arisen between them as of the date this Agreement is executed, except for
those claims set forth in paragraph 8. 
This Agreement and compliance with this Agreement does not constitute an
admission of liability by Agilent.

7.               Byrne understands and expressly agrees that this Agreement extends to
all claims of every nature and kind whatsoever, known or unknown, suspected or
unsuspected, past or present and all rights under Section 1542 of the
California Civil Code and/or any similar statute or law of any other
jurisdiction are expressly waived. 
Section 1542 reads as follows:

A general release
does not extend to claims which the creditor does not know or suspect to exist
in his favor at the time of executing the release, which if known by him must
have materially affected his settlement with the debtor.

8.               This release of
claims does not include: (i) Byrne’s right to enforce the terms of this
Agreement; (ii) claims for vested benefits in which Byrne is entitled,
including but not limited to Workers’ Compensation benefits; (iii) claims that
cannot be released as 

 6
 

a matter of law,
including, but not limited to, claims under Division 3, Article 2 of the
California Labor Code (which includes indemnification rights); and (iv) claims
arising under federal or state securities or employment discrimination laws
where Byrne does not seek personal monetary or other relief.

9.               Byrne acknowledges
and agrees that if he or any other person or entity files a claim or permits to
be filed a claim in a civil action or other legal proceeding for relief,
including personal relief for Byrne (including but not limited to back pay,
front pay, monetary damages, attorneys fees, cost, injunctive or declaratory
relief) against Agilent (except to enforce this Agreement), he will not accept
or be eligible to receive any personal relief from such a claim or cause of action.

10.         It is expressly agreed
that the claims released pursuant to this Agreement include all claims against
employees, officers, directors, attorneys and agents of Agilent in their
individual and representative capacities, whether or not such employees were
acting within the course and scope of their employment.

11.         Byrne represents and
warrants that he has not assigned any such claim or authorized any other person
or entity to assert such claim on Byrne’s behalf. Further, Byrne agrees that
under this Agreement he waives any claim for damages incurred at any time in
the future because of alleged continuing effects of past wrongful conduct
involving any such claims and any right to sue for injunctive relief against
the alleged continuing effects of past wrongful conduct involving such claims.

12.         Each party shall bear its
own costs, expenses, and attorneys’ fees incurred in, or arising out of, or
connected with the negotiation and execution of this Agreement.

13.         Byrne understands and
agrees that, as a condition of this Agreement, he is not entitled to any
employment (including employment as an independent contractor or otherwise)
with Agilent, its subsidiaries or related companies, or any successor, and he
hereby waives any right, or alleged right, of employment or re-employment with
Agilent.  Byrne further agrees not to
apply for employment with Agilent in the future and not to institute or join
any action, lawsuit or proceeding against Agilent, its subsidiaries, related
companies or successors for any failure to employ him. In the event that Byrne
should secure such employment, it is agreed that such employment is voidable
without cause and at the sole discretion of Agilent.

14.           Byrne agrees that the terms, amount and
fact of settlement shall be confidential until Agilent Technologies, Inc. needs
to make any required disclosure of any agreements between Agilent and him as a
part of Agilent’s Securities and Exchange Commission filing requirements.
Therefore, except as may be necessary to enforce the rights contained herein in
an appropriate legal proceeding or as may be necessary to receive professional
services from, an attorney, accountant, or other financial or tax adviser,
Byrne agrees not to disclose the existence or contents of this Agreement or any
past or future related discussions or documentation to anyone, including, but
not limited to, past, present and future employees of Agilent, until such time
of the public filings.  

 7
 

Disclosure is
permitted only to Byrne’s attorney, accountant, financial or tax advisor and
spouse on the condition that such individuals shall be advised of these
limitations, or as otherwise required by law.

15.         At Agilent’s request,
Byrne will give his reasonable cooperation to Agilent in connection with any
legal matter, proceeding or action relating to Agilent.

16.         The terms of this
Agreement are intended by the parties as a final expression of their agreement
with respect to such terms as are included in this Agreement and may not be
contradicted by evidence of any prior or contemporaneous agreement.  The parties further intend that this
Agreement constitutes the complete and exclusive statement of its terms and
that no extrinsic evidence whatsoever may be introduced in any judicial or other
proceeding, if any, involving this Agreement. 
No modification of this Agreement will be effective unless in writing
and signed by both parties hereto.

17.         It is further expressly
agreed and understood that Byrne has not relied upon any advice from Agilent
Technologies, Inc. and/or its attorneys whatsoever as to the taxability,
whether pursuant to federal, state, or local income tax statutes or regulations
or otherwise, of the payments made hereunder and that Byrne will be solely
liable for all tax obligations, if any, arising from payment of the sums
specified herein and shall hold Agilent Technologies, Inc. harmless from any
tax obligations arising from said payment.

18.         Should any provision of
this Agreement be declared or determined by any court of competent jurisdiction
to be wholly or partially illegal, invalid, or unenforceable, the legality,
validity, and enforceability of the remaining parts, terms, or provisions shall
not be affected thereby, and said illegal, unenforceable, or invalid part, term
or provision shall be deemed not to be a part of this Agreement.

19.         This Settlement Agreement
will be governed by and construed in accordance with the laws of the State of
California.

20.         If there is any dispute
arising out of or related to this Agreement, which cannot be settled by good
faith negotiation between the parties, such dispute will be submitted to
JAMS/EndDispute for nonbinding mediation. 
If complete agreement cannot be reached within 45 days of submission to
mediation, any remaining issues will be submitted to JAMS/EndDispute for final
and binding arbitration pursuant to JAMS/EndDispute Arbitration Rules and
Procedures for Employment Disputes with each party bearing their own costs and
attorneys’ fees.

21.         The following notice is provided in accordance with
the provisions of Federal Law:

You are entitled to and
have been given up to twenty-one days (21) days in which to accept the terms of
this Separation Agreement and General Release, although you may accept it any
time within those twenty-one days.

 8
 

You have been told in
writing to consult with an attorney regarding this Agreement.

You have the right to
revoke your acceptance of this Agreement at any time within seven (7) days from
the date you sign it, and this Agreement will not become effective and
enforceable until this seven (7) day revocation period has expired.

To revoke your
acceptance, you must send a written notice of revocation to Jodi Juskie, U.S.
Labor & Employment Counsel, Agilent Technologies, Inc., 900 S. Taft Avenue,
Loveland Colorado, 80537 by 5:00 p.m. on or before the seventh day after you
sign this Agreement.

BYRNE
FURTHER STATES THAT HE HAS HAD THE OPPORTUNITY TO CONSULT WITH THE ATTORNEY OF
HIS CHOICE, THAT HE HAS CAREFULLY READ THIS AGREEMENT, THAT THIS AGREEMENT IS
THE PRODUCT OF NEGOTIATION BETWEEN HIS COUNSEL AND AGILENT’S COUNSEL, THAT HIS
ATTORNEY HAS EXPLAINED THIS AGREEMENT TO HIM, THAT HE HAS HAD AMPLE TIME TO
REFLECT UPON AND CONSIDER ITS CONSEQUENCES, THAT HE FULLY UNDERSTANDS ITS FINAL
AND BINDING EFFECT, THAT THE ONLY PROMISES MADE TO HIM TO SIGN THIS AGREEMENT
ARE THOSE STATED ABOVE AND THAT HE IS SIGNING THIS AGREEMENT VOLUNTARILY.

ACCEPTED AND
AGREED:

AGILENT
TECHNOLOGIES, INC.

	
  By:

  	
  /s/ Jean Halloran

  	
   

  	
  /s/Patrick J. Byrne

  	
   

  
	
  Name:

  	
  Jean Halloran

  	
   

  	
  Name: Patrick J. Byrne

  	
   

  
	
  Title:

  	
  Senior Vice President of Human Resources

  	
   

  	
   

  
	
  Date:

  	
  May 1, 2007

  	
   

  	
   

  	
   

  

 

 9Exhibit 10.20

 

May 1, 2007

InSight Health Services
Corp. and

its Subsidiaries listed on the

signature pages hereto

26250 Enterprise Court

Suite 100

Lake Forest, California 92630

Attention: Chief
Financial Officer

Re:  Payment of
Exchange Consent Fee in Connection with Conversion of Senior Subordinated Notes
to Equity

Ladies and Gentlemen:

Reference is made
to that certain Amended and Restated Loan and Security Agreement  dated September 22, 2005 (as at any time
amended, restated, modified or supplemented, the “Loan Agreement”),
among InSight Health Services Corp.  (individually
and, in its capacity as the representative of the other Borrowers (as defined
below) pursuant to Section 4.4 of the
Loan Agreement, “InSight Health”), a Delaware corporation, and
those subsidiaries of InSight Health listed on the signature pages hereto
(InSight Health and each of its subsidiaries listed on the signature pages
hereto being referred to collectively as “Borrowers,” and individually
as a “Borrower”), the financial institution listed on the signature
pages hereto as “Lender” (together with its successors and permitted
assigns, “Lenders”), and Bank of America, N.A. (“Bank of America”),
a national bank, in its capacity as collateral and administrative agent for the
Lenders (together with its successors in such capacity, “Administrative
Agent”).  Capitalized terms used
herein and not otherwise defined herein shall have the meaning ascribed to such
terms in the Loan Agreement.

Parent filed that
certain Registration Statement on Form S-4 under the Securities Act of 1933, as
amended (the “Securities Act”), on February 16, 2007 (as at any time
amended, supplemented or modified, the “S-4”). As described in the S-4,
Parent has offered to exchange shares of the common stock of Parent for the
valid tender of Senior Subordinated Notes by the holders thereof (the “Exchange
Offer”).  The exchange of shares
of  the common stock of Parent for Senior
Subordinated Notes and the cancellation of Senior Subordinated Notes so
exchanged as described in the S-4 is hereinafter referred to collectively as
the “Exchange Transaction.”

Pursuant to a
letter agreement dated March 15, 2007 (the “March 15 Letter Agreement”),
among the parties hereto, Administrative Agent and Lenders (i) consented to the
Exchange Offer and the amendments to the Senior Subordinated Notes Indenture as
described in the S-4 (the “Indenture Amendments”), the Exchange
Transaction and the change of ownership of Parent that would result therefrom,
and (ii) amended the Loan Agreement in certain respects in connection
therewith.

Borrowers have
informed Administrative Agent and Lenders that Parent intends to file a
prospectus under Rule 424 of the Securities Act modifying the terms of the
Exchange Offer and related consent solicitation (the “Prospectus”).  The Prospectus will, among other things,
provide for the payment of a consent fee (the “Consent Fee”) to the
holders of the Senior Subordinated Notes that consent to the Indenture
Amendments.  Borrowers would pay such
Consent Fee with (i) the proceeds of new Senior Notes to be issued pursuant to
the Senior Note Indenture (the “New Senior Notes”) and (ii) cash on hand
and/or the proceeds of Revolver Loans.

 1
 

Administrative
Agent and Lenders are willing to (i) consent to (a) the Consent Fee and the
payment by Borrowers of the Consent Fee, (b) the issuance of the New Senior
Notes to derive funds necessary to pay a portion of the Consent Fee and the
incurrence by the Borrowers of the Liens and Debt relating to the New Senior
Notes on the same terms and with respect to the same collateral as currently
exists with respect to the Senior Notes, and (c) the issuance of the New Senior
Notes to, and the payment of a Consent Fee to, any Affiliates of the Borrowers
that are equityholders of Parent at the time of such issuance or payment, (ii)
waive the application of any of the provisions in the Loan Agreement that would
prohibit (x) the Consent Fee or payment of the Consent Fee, (y) the issuance of
the New Senior Notes and the incurrence of the Liens and Debt relating to the
New Senior Notes on the same terms and with respect to the same collateral as
currently exists with respect to the Senior Notes, or (z) the issuance of the
New Senior Notes to, and the payment of a Consent Fee to, any Affiliates of the
Borrowers that are equityholders of Parent at the time of such issuance or
payment and (iii) waive the Event of Default resulting from the failure of
InSight Health to make the interest payment on the Senior Subordinated Notes
due May 1, 2007 (the “May SSN Interest Payment”), in each case on the
terms and subject to the conditions set forth herein.

NOW, THEREFORE,
the parties hereto, intending to be bound hereby, agree as follows:

1.             Consent to Incurrence and Payment of Consent Fee and
Issuance of New Senior Notes.  In reliance upon the representations,
warranties, agreements and covenants of Borrowers set forth herein,
Administrative Agent and Lenders hereby consent to (i) the Consent Fee and the
payment by Borrowers of the Consent Fee, (ii) the issuance of the New Senior
Notes in connection therewith, and the incurrence of the Liens and Debt
relating to the New Senior Notes, provided that such Liens and Debt shall be on
the same terms and with respect to the same collateral as currently exists with
respect to the Senior Notes, and (iii) the issuance of the New Senior Notes to,
and the payment of a Consent Fee to, any Affiliates of the Borrowers that are
equityholders of Parent at the time of such issuance or payment; provided that
each of the following conditions is satisfied at the time of payment of the
Consent Fee or issuance of the New Senior Notes and immediately after giving
effect thereto:

(a)           all
of the conditions set forth in clauses (a) and (b) of Section 1 of the March 15
Letter Agreement are timely satisfied;

(b)           after
giving effect to the provisions of this letter agreement, no Default or Event
of Default exists, including, without limitation, any Event of Default arising
from the commencement of any Insolvency Proceeding by or against Parent or any
Borrower;

(c)           irrespective of any original issue
discount in connection with the issuance of the New Senior Notes, the aggregate
stated principal amount of the New Senior Notes shall not exceed $10,000,000;

 2
 

(d)           if New Senior Notes are issued in
connection with payment of the Consent Fee, the New Senior Notes are issued on
or before August 31, 2007;

(e)           the Exchange Transaction is
consummated prior to or concurrently with the issuance of the New Senior Notes
and payment of the Consent Fee; and

(f)            the portion of the Consent Fee that
is derived from cash on hand and/or the proceeds of Revolver Loans does not
exceed $2,500,000 in the aggregate.

To the extent that any provisions of the Loan Agreement or any of the
other Loan Documents (other than this letter agreement and the terms and
conditions set forth herein) would otherwise restrict (A) Borrowers’ ability to
agree to pay or to pay the Consent Fee, (B) the issuance of the New Senior
Notes and the incurrence of the Liens and Debt relating to the New Senior Notes
on the same terms and with respect to the same collateral as currently exists
with respect to the Senior Notes, or (C) the issuance of the New Senior Notes
to, or the payment of a Consent Fee to, any Affiliates of Borrowers that are
equityholders of Parent at the time of such issuance or payment, Administrative
Agent and Lenders hereby waive the application of such provisions subject to
the conditions set forth above.  The foregoing waiver shall not extend
to, or be deemed a waiver with respect to, any matter other than the matters
specified in clauses (A), (B), and (C) of the prior sentence.

2.             Additional Agreements.  (a) 
The Administrative Agent and Lenders hereby waive the Event of Default
existing under Section 12.1.5 of the Loan Agreement as a result of the failure
of InSight Health to make the May SSN Interest Payment on May 1, 2007, provided
that if such payment is not made on or before May 31, 2007 with respect to the
Senior Subordinated Notes that are not tendered as part of the Exchange Transaction,
such failure shall constitute an Event of Default under the Loan Agreement that
is not waived hereby.

(b)   The
Administrative Agent and the Lenders hereby agree that the last sentence of
Section 9.1.9 of the Loan Agreement is hereby amended in its entirety to read
as follows:

“Since March 31, 2005, there has been no material adverse change in the
consolidated financial condition of the Borrowers and such other Persons shown
on the Consolidated balance sheet as of such date, except as set forth in any
filings made by Parent or Borrowers with the SEC that have been provided to
Administrative Agent and Lenders prior to May 1, 2007.”

3.             No Novation, Etc.  The parties hereto acknowledge and agree
that, except as set forth herein, nothing in this letter agreement shall be
deemed to amend, modify or waive any provision of the Loan Agreement, the March
15 Letter Agreement or any of the other Loan Documents, each of which shall
remain in full force and effect.  This
letter agreement is not intended to be, nor shall it be construed to create, a
novation or accord and satisfaction, and the Loan Agreement as herein modified
shall continue in full force and effect. Nothing in this letter agreement is
intended to abrogate, amend or alter section 8.2.5 of the Loan Agreement or to
require Lenders to make any Revolver Loan at a time at which Borrowers do not
have availability to obtain such Revolver Loan.

 3
 

4.             Ratification and
Reaffirmation.  Borrowers
hereby ratify and reaffirm the Obligations, each of the Loan Documents and all
of Borrowers’ covenants, duties, indebtedness and liabilities under the Loan
Documents.

5.             Acknowledgements and Stipulations; Representation and
Warranties.
By its signature below, each Borrower (a) acknowledges and stipulates that (i)
the Loan Agreement and the other Loan Documents executed by such Borrower are
legal, valid and binding obligations of such Borrower that are enforceable
against such Borrower in accordance with the terms thereof, except as the
enforceability thereof maybe limited by bankruptcy, insolvency or other similar
laws of general application affecting the enforcement of creditors’ rights,
(ii) all of the Obligations of such Borrower are owing and payable without
defense, offset or counterclaim (and to the extent there exists any such
defense, offset or counterclaim on the date hereof, the same is hereby waived
by each Borrower), (iii) the security interests and liens granted by such
Borrower in favor of Administrative Agent are duly perfected, first priority
security interests and Liens (subject only to those Permitted Liens that
are expressly permitted by the terms of the Loan Agreement to have
priority over the Liens of Administrative Agent), and (iv) the Loan
Agreement and any actions taken under the Loan Agreement are hereby ratified
and approved by such Borrower; and (b) represents and warrants to
Administrative Agent and Lenders, to induce Administrative Agent and Lenders to
enter into this letter agreement, that (i) the execution, delivery and
performance of this letter agreement has been duly authorized by all requisite
corporate or limited liability company action on the part of such Borrower,
(ii) all of the representations and warranties made by such Borrower in the
Loan Agreement and the other Loan Documents are true and correct in all
material respects on and as of the date hereof, except to the extent that any
such representation or warranty is stated to relate to an earlier date, in
which case such representation or warranty shall be true and correct in all
material respects on and as of such earlier date, and (iii) to the best of such
Borrower’s knowledge, there exists no claim or cause of action of any kind or
nature, whether absolute or contingent, disputed or undisputed, at law or in
equity, that such Borrower has or has ever had against Administrative Agent or
any Lender arising under or in connection with any of the Loan Documents (and
to the extent there exists any such claim or cause of action on the date
hereof, the same is hereby waived by such Borrower).

6.             Expenses.   Borrowers agree to pay, on demand, all reasonable out-of-pocket
costs and expenses incurred by Administrative Agent and Lenders in connection
with the preparation, negotiation and execution of this letter agreement, any
other Loan Documents executed pursuant hereto and any and all amendments,
modifications and supplements thereto, including the reasonable costs and fees
of Administrative Agent’s outside legal counsel.

 4
 

7.             Miscellaneous.  This letter agreement shall be governed by
and construed in accordance with the internal laws of the State of New
York.  This letter agreement shall be
binding upon an inure to the benefit of the parties and their respective
successors and assigns.  This letter
agreement may be executed in any number of counterparts and by different
parties to this letter agreement on separate counterparts, each of which when
so executed, shall be deemed an original, but all such counterparts shall
constitute one and the same agreement.  Any
signature delivered by a party by facsimile transmission or portable document
format by electronic mail shall be deemed to be an original signature
hereto.  To the fullest extent permitted by Applicable Law, the parties hereto
each hereby waives the right to trial by jury in any action, suit, counterclaim
or proceeding arising out of or related to this letter agreement.

[Signatures
appear on following page]

 5
 

This letter agreement
shall be effective upon Administrative Agent’s receipt of counterparts hereof
duly executed by Lenders and Borrowers.

	
  

  	
   

  	
  Very truly yours

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  ADMINISTRATIVE AGENT:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BANK OF AMERICA, N.A.,

  
	
   

  	
   

  	
  as Administrative Agent

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Seth Benefield

  	
   

  
	
   

  	
   

  	
  Name:

  	
    /s/ Seth Benefield

  	
   

  
	
   

  	
   

  	
  Title:

  	
  Vice President

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  LENDER:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BANK OF AMERICA, N.A., as
  Lender

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Seth Benefield

  	
   

  
	
   

  	
   

  	
  Name:

  	
    /s/ Seth Benefield

  	
   

  
	
   

  	
   

  	
  Title:

  	
  Vice President

  	
   

  
								

 

 

[Signatures continued on following page]

 6
 

 

	
  

  	
   

  	
    BORROWERS:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  INSIGHT
  HEALTH SERVICES CORP.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  	
   

  
	
   

  	
   

  	
   

  	
  Mitch C. Hill, Executive Vice
  President and Chief

  Financial Officer

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  WILKES-BARRE IMAGING, L.L.C.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  InSight Health Corp., as the sole member and

  sole manager

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch
  C. Hill, Executive Vice President

  and Chief Financial Officer

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MRI ASSOCIATES, L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  InSight Health Corp., as the general partner

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch
  C. Hill, Executive Vice President

  and Chief Financial Officer

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  VALENCIA
  MRI, LLC

  
	
   

  	
   

  	
  ORANGE COUNTY REGIONAL PET CENTER-

  IRVINE, LLC

  
	
   

  	
   

  	
  SAN FERNANDO VALLEY REGIONAL PET

  CENTER, LLC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  InSight Health Corp., as the sole member

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch
  C. Hill, Executive Vice President

  and Chief Financial Officer

  
							

 

 

[Signatures continued on
following page]

 7
 

 

	
  

  	
   

  	
  PARKWAY IMAGING CENTER, LLC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Mitch C. Hill

  
	
   

  	
   

  	
  Title:

  	
  Manager

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  INSIGHT HEALTH CORP.

  
	
   

  	
   

  	
  OPEN MRI, INC.

  
	
   

  	
   

  	
  MAXUM HEALTH CORP.

  
	
   

  	
   

  	
  RADIOSURGERY CENTERS, INC.

  
	
   

  	
   

  	
  DIAGNOSTIC SOLUTIONS CORP.

  
	
   

  	
   

  	
  MAXUM HEALTH SERVICES CORP.

  
	
   

  	
   

  	
  MAXUM HEALTH SERVICES OF NORTH

  TEXAS, INC.

  
	
   

  	
   

  	
  MAXUM HEALTH SERVICES OF DALLAS,

  INC.

  
	
   

  	
   

  	
  NDDC, INC.

  
	
   

  	
   

  	
  SIGNAL MEDICAL SERVICES, INC.

  
	
   

  	
   

  	
  INSIGHT IMAGING SERVICES CORP.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING,

  INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING

  CENTERS, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING-

  BILTMORE, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE OPEN MRI-EAST MESA,

  INC.

  
	
   

  	
   

  	
  TME ARIZONA, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING-

  FREMONT, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING-

  SAN FRANCISCO, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE OPEN MRI- GARLAND,

  INC.

  
	
   

  	
   

  	
  IMI OF ARLINGTON, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING-

  FAIRFAX, INC.

  
	
   

  	
   

  	
  IMI OF KANSAS CITY, INC.

  
	
   

  	
   

  	
  COMPREHENSIVE MEDICAL IMAGING-

  BAKERSFIELD, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  	
   

  
	
   

  	
   

  	
   

  	
  Mitch C. Hill, Executive Vice
  President and

  Chief Financial Officer

  
						

 

 

[Signatures
continued on following page]

 8
 

 

	
  

  	
   

  	
  COMPREHENSIVE OPEN MRI-

  CARMICHAEL/FOLSOM, LLC

  
	
   

  	
   

  	
  SYNCOR
  DIAGNOSTICS SACRAMENTO, LLC

  
	
   

  	
   

  	
  SYNCOR
  DIAGNOSTICS BAKERSFIELD, LLC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  Comprehensive Medical Imaging, Inc. and

  Comprehensive Medical Imaging Centers,

  Inc., as the members

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch
  C. Hill, Executive Vice President

  and Chief Financial Officer

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PHOENIX REGIONAL PET CENTER-

  THUNDERBIRD, LLC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  Comprehensive Medical Imaging Centers,

  Inc., as the sole member

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch C.
  Hill, Executive Vice President

  and Chief Financial Officer

  

 

 

[Signatures continued on
following page]

 9
 

 

	
  

  	
   

  	
  MESA MRI

  MOUNTAIN VIEW MRI

  LOS GATOS IMAGING CENTER

  WOODBRIDGE MRI

  JEFFERSON MRI-BALA

  JEFFERSON MRI

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  Comprehensive
  Medical Imaging, Inc.

  and Comprehensive Medical Imaging

  Centers, Inc., as the members

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
  /s/ Mitch C. Hill

  
	
   

  	
   

  	
   

  	
   

  	
  Mitch C. Hill, Executive Vice
  President

  and Chief Financial Officer

  

 

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]